In breast cancer, several cohort analyses report that ERβ (especially ERβ1) expression correlates with more favorable outcomes, supporting a tumor-suppressive role; however, results vary by ERβ isoform, cellular localization, ERα status, and endocrine therapy exposure, with some series noting adverse signals in specific tamoxifen-treated subgroups. Here, ESR2 is linked to neoplasm.